All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Novartis AG is expanding its cardiovascular disease therapy pipeline through its acquisition of San Mateo, Calif.-based biotech Corthera Inc., giving the Swiss pharma giant exclusive worldwide rights to relaxin, a recombinant version of a naturally occurring human peptide currently in Phase III development as a treatment for acute decompensated heart failure (ADHF). (BioWorld Today)
WASHINGTON - The Bush administration's proposed 2009 fiscal year budget for the FDA includes not only a 5.7 percent increase but a plan to seek authority to allow the agency to approve abbreviated applications for certain biologic products, or follow-on biologics. (BioWorld Today)
Study results showed that Acorda Therapeutics Inc.'s multiple sclerosis drug Fampridine-SR does not increase a patient's risk of developing cardiac arrhythmias, or an irregular heart beat. (BioWorld Today)
A week after initiating a Phase IIa study of its chronic hepatitis C virus (HCV) drug PSI-7977, Pharmasset Inc. priced a public offering of 1.6 million shares of its common stock at $18.75. (BioWorld Today)
>WASHINGTON – Irish firm Elan Corp. plc is the latest company snared by the Department of Justice (DOJ) for illegally marketing drug products, with the Dublin-based company agreeing to pay about $203.5 million to resolve criminal and civil charges of off-label promotion of its epilepsy drug Zonegran (zonisamide).
